← Leaderboards
Beth A Overmoyer
Case Western Reserve University
$760,943
Attributed
$760,943
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$760,943 · 6
By mechanism
K23$486,000 · 1
P30$157,740 · 1
M01$117,203 · 4
Top collaborators
No co-investigators on record.
Most similar at Case Western Reserve University
Same institution · by research overlap
- William Schiemann$12,636,493
- Bingcheng Wang$12,028,840
- Zhenghe Wang$15,658,585
- Zheng-Rong Lu$13,267,567
- Stanton L Gerson$68,151,957
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectHuman Therapy EvaluationClinical ResearchNeoplasm /Cancer ChemotherapyCombination ChemotherapyPaclitaxelBreast NeoplasmsDoxorubicinAngiogenesisFenretinideNutrition Related TagCis Platinum CompoundNeoplasm /Cancer Blood SupplyMetastasisCombination Cancer TherapyClinical Trial Phase IPatient Oriented ResearchAngiogenesis InhibitorsClinical Trial Phase IiClinical TrialsDosageBiomedical FacilityPharmacokineticsMonoclonal Antibody
Grant awards (11)
TRANSLATIONAL RESEARCH IN BREAST CANCER$108,000
K23 · FY2004 · CA
Bevacizumab and docetaxel for locally advanced breast cancer$65,367
M01 · FY2004 · RR
Fenretinide + paclitaxel + cisplatin for advanced solid tumors$44,858
M01 · FY2004 · RR
SU5416 and doxorubicin in inflammatory breast cancer$4,040
M01 · FY2004 · RR
Pegylated liposomal doxorubicin + vinorelbine + gemcitabine for solid tumors$2,938
M01 · FY2004 · RR
TRANSLATIONAL RESEARCH IN BREAST CANCER$108,000
K23 · FY2003 · CA
CORE--CLINICAL TRIALS FACILITY$78,870
P30 · FY2002 · CA
TRANSLATIONAL RESEARCH IN BREAST CANCER$54,000
K23 · FY2002 · CA
TRANSLATIONAL RESEARCH IN BREAST CANCER$108,000
K23 · FY2001 · CA
CORE--CLINICAL TRIALS FACILITY$78,870
P30 · FY2001 · CA
TRANSLATIONAL RESEARCH IN BREAST CANCER$108,000
K23 · FY2000 · CA